T cell receptor (TCR), or CD3 complex, or costimulatory receptors (see detail below; no single canonical molecule corresponds to the query) (TCR, CD3, CD28 (depends on specific molecule; none for the generic modulation process))

Modulation of T cell responses in the immune system refers to the therapeutic alteration of T cell activation, function, and fate to treat disease. It encompasses strategies that target key molecules such as the T cell receptor (TCR), the associated CD3 complex, and costimulatory or inhibitory receptors (CD28, CTLA-4, PD-1). These molecules govern the recognition of antigens via major histocompatibility complex (MHC) presentation, initiate intracellular signaling cascades, and regulate cytokine production, proliferation, and immune effector functions[1][2][3][4][5][6][7]. Drugs may enhance or suppress T cell activation for the treatment of cancer, autoimmune disorders, or infections, but therapies carry risks such as excessive inflammation, autoimmune reactions, or immunosuppression. Because "Immune system T cell response modulation" is not a specific molecule or receptor, precise information depends on the exact molecular target referenced (e.g., TCR, CD3, CD28, CTLA-4, PD-1).[1][2][3][4][7]

Other names

T cell activation modulationmodulation of T cell responseimmunomodulation via T cellsT cell costimulationimmune checkpoint modulation

Blockade of inhibitory checkpoints to boost T cell activation (PD-1/PD-L1, CTLA-4 inhibition); Costimulatory agonism (CD28, 4-1BB, OX40 activation); Direct activation or suppression of T cells (CD3 agonists/antagonists); Inhibition of T cell signaling (calcineurin inhibitors); Adoptive cell transfer (CAR-T cells introduce engineered T cell receptors)